Apr. 15 at 1:48 PM
$SPPL 🧬 NASDAQ:МYNZ — Under
$3.50 Won’t Last. Read That Again.
While everyone’s looking the other way, Маіnz Bіоmed is sitting on:
🔬 mRNA diagnostics,
🧪 New TRDMT1-linked DNA repair data,
💉 Blood-based biomarkers for pancreatic cancer,
⚙️ Upgraded ColoAlert now enrolling DETECT 2 patients.
This isn’t just another biotech.
It’s a microfloat clinical-stage company with a global footprint, pushing into liquid biopsy + precision oncology.
📈 Chart’s tightening. Volume waking up. No dilution. No fluff.
🧠 R/R is stupid good here.
$4 breakout could come fast — and if it hits, there’s room for way more.
Biotech’s bleeding? Cool. МYNZ isn’t.
This thing’s been quietly loading while the rest of the sector panics.
I’m in. Early. Not watching. Positioning.
DYOR — or chase it later like they always do.
